Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Emerging biologics in severe a...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Emerging biologics in severe asthma
Bibliographic Details
Main Authors:
Pavord, I
,
Hilvering, B
,
Shrimanker, R
Format:
Journal article
Published:
Elsevier
2016
Holdings
Description
Similar Items
Staff View
Similar Items
Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
by: Shrimanker, R, et al.
Published: (2017)
Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
by: Xue, L, et al.
Published: (2015)
Management and mechanisms of severe eosinophilic asthma
by: Shrimanker, R
Published: (2020)
Exacerbations of severe asthma in patients treated with mepolizumab
by: Shrimanker, R, et al.
Published: (2018)
Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
by: Howell, I, et al.
Published: (2024)